MUMBAI, India, Aug. 27, 2020 /PRNewswire/ -- Piramal Pharma Solutions, a leading contract development and manufacturing organization (CDMO), today announced that the company will be partnering with Epirium Bio on an exclusive manufacturing relationship for new orphan drugs targeting rare diseases with high unmet needs.
SAN DIEGO--(BUSINESS WIRE)--Epirium Bio Inc., a clinical-stage biopharmaceutical company pursuing novel and clinically significant therapeutic approaches for neuromuscular, neurodegenerative and mitochondrial disorders, today announced enrollment of the first participants in its Phase 1 clinical trial of EPM-01 in Becker muscular dystrophy. EPM-01 is a novel, oral, synthetic compound that has demonstrated compelling proof-of-concept in multiple preclinical and clinical studies of mitochondrial dysfunction. The Phase 1 study will be conducted by investigators at three leading academic centers in the United States, including University of California, Davis, and Washington University School of Medicine, St. Louis.
SAN DIEGO--(BUSINESS WIRE)--Epirium Bio Inc., a clinical-stage biopharmaceutical company focused on mitochondrial biogenesis and complementary therapeutic approaches as a means to addressing neuromuscular diseases and neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its unique, orally available, synthetic flavanol EB 002 ((+)-epicatechin) for the treatment of Duchenne and Becker muscular dystrophy. Orphan-drug designation is granted to support development of medicines for patient populations fewer than 200,000 people in the U.S. The company will initially focus on advancing its treatment in Becker muscular dystrophy.
Epirium Bio, Inc. (“Epirium”) formerly, Cardero Therapeutics, Inc., today announced it has raised $85 million in Series A financing provided by Longitude Capital, ARCH Venture Partners, Bluebird Ventures, Adams Street Partners, Vertex Ventures HC, and The Longevity Fund. Epirium is a clinical stage biopharmaceutical company developing therapeutics that optimize both tissue bioenergetics and structure through a novel mechanism of action discovered by the company.